Senti Biosciences Inc SNTI
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-05-26 |
| Shares Out. | 31,140,000 |
| Website | sentibio.com ↗ |
| Phone | 13026587581 |
| Employees | 39 |
| Revenue | $16,000 |
| Gross Profit | $16,000 |
| Net Income | -$4.2M |
| Free Cash Flow | -$37.1M |
| Total Assets | $38.2M |
| Total Liabilities | $35.7M |
| Equity | $2.6M |
About Senti Biosciences Inc
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Senti Biosciences Inc is a publicly traded company under the ticker symbol SNTI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)